First Time Loading...

Repare Therapeutics Inc
NASDAQ:RPTX

Watchlist Manager
Repare Therapeutics Inc Logo
Repare Therapeutics Inc
NASDAQ:RPTX
Watchlist
Price: 3.15 USD 4.3% Market Closed
Updated: Apr 20, 2024

Intrinsic Value

RPTX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient population... [ Read More ]

The intrinsic value of one RPTX stock under the Base Case scenario is 6.65 USD. Compared to the current market price of 3.15 USD, Repare Therapeutics Inc is Undervalued by 53%.

Key Points:
RPTX Intrinsic Value
Base Case
6.65 USD
Undervaluation 53%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Repare Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling RPTX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Repare Therapeutics Inc

Provide an overview of the primary business activities
of Repare Therapeutics Inc.

What unique competitive advantages
does Repare Therapeutics Inc hold over its rivals?

What risks and challenges
does Repare Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Repare Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Repare Therapeutics Inc.

Provide P/S
for Repare Therapeutics Inc.

Provide P/E
for Repare Therapeutics Inc.

Provide P/OCF
for Repare Therapeutics Inc.

Provide P/FCFE
for Repare Therapeutics Inc.

Provide P/B
for Repare Therapeutics Inc.

Provide EV/S
for Repare Therapeutics Inc.

Provide EV/GP
for Repare Therapeutics Inc.

Provide EV/EBITDA
for Repare Therapeutics Inc.

Provide EV/EBIT
for Repare Therapeutics Inc.

Provide EV/OCF
for Repare Therapeutics Inc.

Provide EV/FCFF
for Repare Therapeutics Inc.

Provide EV/IC
for Repare Therapeutics Inc.

Show me price targets
for Repare Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Repare Therapeutics Inc?

How accurate were the past Revenue estimates
for Repare Therapeutics Inc?

What are the Net Income projections
for Repare Therapeutics Inc?

How accurate were the past Net Income estimates
for Repare Therapeutics Inc?

What are the EPS projections
for Repare Therapeutics Inc?

How accurate were the past EPS estimates
for Repare Therapeutics Inc?

What are the EBIT projections
for Repare Therapeutics Inc?

How accurate were the past EBIT estimates
for Repare Therapeutics Inc?

Compare the revenue forecasts
for Repare Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Repare Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Repare Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Repare Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Repare Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Repare Therapeutics Inc with its peers.

Analyze the financial leverage
of Repare Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Repare Therapeutics Inc.

Provide ROE
for Repare Therapeutics Inc.

Provide ROA
for Repare Therapeutics Inc.

Provide ROIC
for Repare Therapeutics Inc.

Provide ROCE
for Repare Therapeutics Inc.

Provide Gross Margin
for Repare Therapeutics Inc.

Provide Operating Margin
for Repare Therapeutics Inc.

Provide Net Margin
for Repare Therapeutics Inc.

Provide FCF Margin
for Repare Therapeutics Inc.

Show all solvency ratios
for Repare Therapeutics Inc.

Provide D/E Ratio
for Repare Therapeutics Inc.

Provide D/A Ratio
for Repare Therapeutics Inc.

Provide Interest Coverage Ratio
for Repare Therapeutics Inc.

Provide Altman Z-Score Ratio
for Repare Therapeutics Inc.

Provide Quick Ratio
for Repare Therapeutics Inc.

Provide Current Ratio
for Repare Therapeutics Inc.

Provide Cash Ratio
for Repare Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Repare Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Repare Therapeutics Inc?

What is the current Free Cash Flow
of Repare Therapeutics Inc?

Financials

Balance Sheet Decomposition
Repare Therapeutics Inc

Current Assets 243.7m
Cash & Short-Term Investments 223.6m
Receivables 15.3m
Other Current Assets 4.7m
Non-Current Assets 10.2m
PP&E 7.5m
Other Non-Current Assets 2.7m
Current Liabilities 39.1m
Accounts Payable 2.4m
Accrued Liabilities 26.3m
Other Current Liabilities 10.4m
Non-Current Liabilities 2.7m
Other Non-Current Liabilities 2.7m
Efficiency

Earnings Waterfall
Repare Therapeutics Inc

Revenue
51.1m USD
Operating Expenses
-167.4m USD
Operating Income
-116.2m USD
Other Expenses
22.4m USD
Net Income
-93.8m USD

Free Cash Flow Analysis
Repare Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

RPTX Profitability Score
Profitability Due Diligence

Repare Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
ROIC is Increasing
Declining ROE
Negative Revenue Growth Forecast
23/100
Profitability
Score

Repare Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

RPTX Solvency Score
Solvency Due Diligence

Repare Therapeutics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
65/100
Solvency
Score

Repare Therapeutics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RPTX Price Targets Summary
Repare Therapeutics Inc

Wall Street analysts forecast RPTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RPTX is 18.02 USD with a low forecast of 8.08 USD and a high forecast of 30.45 USD.

Lowest
Price Target
8.08 USD
157% Upside
Average
Price Target
18.02 USD
472% Upside
Highest
Price Target
30.45 USD
867% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

RPTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

RPTX Price
Repare Therapeutics Inc

1M 1M
-40%
6M 6M
-28%
1Y 1Y
-67%
3Y 3Y
-90%
5Y 5Y
-90%
10Y 10Y
-90%
Annual Price Range
3.15
52w Low
3.02
52w High
13.01
Price Metrics
Average Annual Return -20.04%
Standard Deviation of Annual Returns 32.68%
Max Drawdown -93%
Shares Statistics
Market Capitalization 132.9m USD
Shares Outstanding 42 182 200
Percentage of Shares Shorted 2.72%

RPTX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Repare Therapeutics Inc Logo
Repare Therapeutics Inc

Country

Canada

Industry

Biotechnology

Market Cap

132.9m USD

Dividend Yield

0%

Description

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 152 full-time employees. The company went IPO on 2020-06-19. The firm is focused on the development of synthetic lethality (SL) based therapies to patients with cancer. The company uses genome wide, SNIPRx platform to systematically discover and develop targeted cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The firm is developing its pipeline of SL product candidates, including its lead product candidate, RP-3500, a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related (ATR) protein kinase for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated (ATM) kinase gene. Its preclinical programs include RP-6306 Protein Kinase Membrane-associated tYrosine- and Threonine- specific cdc-2 inhibitory (PKMYT1)kinase SL inhibitor, in advanced solid tumors.

Contact

QUEBEC
ST-LAURENT
7210 Frederick-Banting, Suite 100
+18574127018.0
http://www.reparerx.com/

IPO

2020-06-19

Employees

152

Officers

President, CEO & Director
Mr. Lloyd Mitchell Segal
Executive VP & Chief Scientific Officer
Dr. Michael Zinda Ph.D.
Executive VP & Chief Medical Officer
Dr. Maria Koehler M.D., Ph.D.
Co-Founder
Dr. Agnel Sfeir Ph.D.
Executive VP & CFO
Mr. Steve Forte
Executive Vice President of Human Resource
Mr. Daniel Belanger
Show More
Executive Vice President of Discovery
Mr. Cameron Black
Executive VP & Chief Business Officer
Dr. Kim A. Seth Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one RPTX stock?

The intrinsic value of one RPTX stock under the Base Case scenario is 6.65 USD.

Is RPTX stock undervalued or overvalued?

Compared to the current market price of 3.15 USD, Repare Therapeutics Inc is Undervalued by 53%.